A resolution designating September 2023 as "National Cholesterol Education Month" and September 30, 2023, as LDL-C Awareness Day.

Bill: 118-sres-496
Sponsor: full_name: Sen. Hyde-Smith, Cindy [R-MS]
Introduced: 2023-12-13
Policy area: Health
Subjects: Cardiovascular and respiratory health

Commemorative events and holidays

Health promotion and preventive care
Latest action: action_date: 2024-02-27
text: Resolution agreed to in Senate without amendment and with a preamble by Unanimous Consent. (consideration: CR S1014; text: 12/13/2023 CR S5964)

Summaries:
action_date: 2023-12-13
action_desc: Introduced in Senate
text: <p class="MsoNormal" style="line-height: normal;">This resolution designates National Cholesterol Education Month and Low-Density Lipoprotein Cholesterol (LDL-C) Awareness Day. The resolution also encourages all individuals in the United States to know their LDL-C number. High levels of LDL-C increase the risk of heart disease and stroke.</p> <p class="MsoNormal" style="line-height: normal;" />

action_date: 2024-02-27
action_desc: Passed Senate
text: <div><br /></div> <div>This resolution designates National Cholesterol Education Month and Low-Density Lipoprotein Cholesterol (LDL-C) Awareness Day. The resolution also encourages all individuals in the United States to know their LDL-C number. High levels of LDL-C increase the risk of heart disease and stroke. </div> <p class="MsoNormal" style="line-height: normal;"> </p>

tv_txt: III 118th CONGRESS 2d Session S. RES. 496 IN THE SENATE OF THE UNITED STATES December 13, 2023 Mrs. Hyde-Smith (for herself, Mr. Peters , and Mrs. Blackburn ) submitted the following resolution; which was referred to the Committee on the Judiciary February 27, 2024 Committee discharged; considered and agreed to RESOLUTION Designating September 2023 as National Cholesterol Education Month and September 30, 2023, as LDL–C Awareness Day.

Whereas cardiovascular disease is the leading cause of death for men and women; Whereas projected rates of cardiovascular disease are expected to increase significantly in the United States by 2060; Whereas, compared to urban areas, rural areas in the United States have higher death rates for cardiovascular disease and stroke, and a 40 percent higher prevalence of cardiovascular disease; Whereas risk factors contributing to cardiovascular disease and poor health outcomes include elevated low density lipoprotein cholesterol (referred to in this preamble as LDL–C ), high levels of lipoprotein(a) cholesterol, hypertension, obesity, low awareness of personal risk factors, genetics, geographic location, and inequitable access to care; Whereas lipoprotein(a) cholesterol is predominantly genetically inherited and can build up in the walls of blood vessels creating cholesterol deposits, or plaques, and lead to atherosclerotic cardiovascular disease; Whereas LDL–C is a modifiable risk factor for cardiovascular disease and having lower LDL–C is associated with a reduced risk of heart attack and stroke; Whereas more than 25.5 percent of adults in the United States have high LDL–C; Whereas more than 200 studies with more than 2,000,000 patients have broadly established that elevated LDL–C unequivocally causes atherosclerotic cardiovascular disease; Whereas atherosclerotic cardiovascular disease is the build-up of cholesterol plaque within the walls of arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as heart attacks and strokes; Whereas the resources needed to bend the curve on cardiovascular disease exist, yet 71 percent of hypercholesterolemia patients at high risk of a cardiovascular event never achieve recommended LDL–C treatment guideline thresholds; Whereas only 33 percent of individuals with atherosclerotic cardiovascular disease who are taking statins, a guideline recommended lipid lowering therapy, actually achieve LDL–C goals; Whereas, although clinical guidelines recommend that a patient hospitalized for heart attack receive an LDL–C test in the 90 days following discharge from a hospital, only 27 percent of patients receive such test; Whereas African-American adults are less likely to receive an LDL–C test in the 90 days following discharge from a hospital, despite having a higher prevalence of cardiovascular disease; Whereas significant gaps in care lead to subsequent cardiovascular events; Whereas the Million Hearts program seeks to improve access to and quality of care to reduce heart disease, stroke, and death; and Whereas September is recognized as National Cholesterol Education Month to raise awareness of cardiovascular disease and the importance of knowing one’s LDL–C number: Now, therefore, be it

That the Senate— (1) encourages all individuals in the United States to know their low density lipoprotein cholesterol (referred to in this resolution as LDL–C ) number; (2) designates September 2023, as National Cholesterol Education Month ; (3) designates September 30, 2023, as LDL–C Awareness Day ; and (4) recognizes the urgent need for screening and treating of elevated LDL–C to reduce the risk of cardiovascular disease and cardiovascular events, including heart attacks and strokes.

tv_txt: III 118th CONGRESS 1st Session S. RES. 496 IN THE SENATE OF THE UNITED STATES December 13, 2023 Mrs. Hyde-Smith (for herself and Mr. Peters ) submitted the following resolution; which was referred to the Committee on the Judiciary RESOLUTION Designating September 2023 as National Cholesterol Education Month and September 30, 2023, as LDL–C Awareness Day.

Whereas cardiovascular disease is the leading cause of death for men and women; Whereas projected rates of cardiovascular disease are expected to increase significantly in the United States by 2060; Whereas, compared to urban areas, rural areas in the United States have higher death rates for cardiovascular disease and stroke, and a 40 percent higher prevalence of cardiovascular disease; Whereas risk factors contributing to cardiovascular disease and poor health outcomes include elevated low density lipoprotein cholesterol (referred to in this preamble as LDL–C ), high levels of lipoprotein(a) cholesterol, hypertension, obesity, low awareness of personal risk factors, genetics, geographic location, and inequitable access to care; Whereas lipoprotein(a) cholesterol is predominantly genetically inherited and can build up in the walls of blood vessels creating cholesterol deposits, or plaques, and lead to atherosclerotic cardiovascular disease; Whereas LDL–C is a modifiable risk factor for cardiovascular disease and having lower LDL–C is associated with a reduced risk of heart attack and stroke; Whereas more than 25.5 percent of adults in the United States have high LDL–C; Whereas more than 200 studies with more than 2,000,000 patients have broadly established that elevated LDL–C unequivocally causes atherosclerotic cardiovascular disease; Whereas atherosclerotic cardiovascular disease is the build-up of cholesterol plaque within the walls of arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as heart attacks and strokes; Whereas the resources needed to bend the curve on cardiovascular disease exist, yet 71 percent of hypercholesterolemia patients at high risk of a cardiovascular event never achieve recommended LDL–C treatment guideline thresholds; Whereas only 33 percent of individuals with atherosclerotic cardiovascular disease who are taking statins, a guideline recommended lipid lowering therapy, actually achieve LDL–C goals; Whereas, although clinical guidelines recommend that a patient hospitalized for heart attack receive an LDL–C test in the 90 days following discharge from a hospital, only 27 percent of patients receive such test; Whereas African-American adults are less likely to receive an LDL–C test in the 90 days following discharge from a hospital, despite having a higher prevalence of cardiovascular disease; Whereas significant gaps in care lead to subsequent cardiovascular events; Whereas the Million Hearts program seeks to improve access to and quality of care to reduce heart disease, stroke, and death; and Whereas September is recognized as National Cholesterol Education Month to raise awareness of cardiovascular disease and the importance of knowing one’s LDL–C number: Now, therefore, be it

That the Senate— (1) encourages all individuals in the United States to know their low density lipoprotein cholesterol (referred to in this resolution as LDL–C ) number; (2) designates September 2023, as National Cholesterol Education Month ; (3) designates September 30, 2023, as LDL–C Awareness Day ; and (4) recognizes the urgent need for screening and treating of elevated LDL–C to reduce the risk of cardiovascular disease and cardiovascular events, including heart attacks and strokes.